"Principles of Clinical Pharmacology" is a successful survey covering the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development. This essential reference continues to focus on the basics of clinical pharmacology for the development, evaluation, and clinical use of pharmaceutical products while also addressing the most recent advances in the field. Written by leading experts in academia, industry, clinical and regulatory settings, the third edition has been thoroughly updated to provide readers with an ideal reference covering the wide range of important topics impacting clinical pharmacology as the discipline plays an increasingly significant role in drug development and regulatory science.

The Third Edition has been endorsed by the American Society for Clinical Pharmacology and Therapeutics

* Includes new chapters on imaging and the pharmacogenetic basis of adverse drug reactions. * Offers an expanded regulatory section that addresses US and international issues and guidelines. * Provides extended coverage of earlier chapters on transporters, pharmacogenetics and biomarkers and also illustrates the impact of gender on drug response. * Presents a broadened discussion of clinical trials from Phase 1 to incorporate Phases II and III.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
This volume is essential for internal medicine physicians and general practitioners who prescribe antibiotic drugs, like penicillin and tetracycline that cure bacterial infections, and antiviral drugs used to treat patients with HIV and herpes viruses.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only antimicrobial drugs, but also all other drugs that act in an anti-microbial manner
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician.

Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment of heart failure, angina, angina pectoris, and cardiac arrhythmia and enable practitioners to prescribe preventative treatments with medications such as blood pressure reducers, aspirin, and cholesterol-lowering drugs, as well as drugs used for more aggressive therapy.

The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.

This volume is critical for any health professional involved in the administration of cardiovascular mediations.
Surpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysisComplete index of drug namesMost complete cross referencing of drug-drug interactions availableExtensive references to primary and secondary literatureAlso includes information on adverse effects in pregnancy

The book is divided into six sections:

Drugs used to treat hypertension, heart failure and angina pectorisDiuretics - a general introduction to their adverse effects, followed by monographs on individual drugsAntidysrhythmic drugs - a general introduction to their adverse effects, followed by monographs on individual drugsDrugs that act on the cerebral and peripheral circulationsAnticoagulants, thrombolytic agents, and anti-platelet drugsCardiovascular adverse effects of non-cardiovascular drugs "

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Many controlled release veterinary drug delivery systems (CRVDDS) are presently in use, and recently there has been a host of new CRVDDS within veterinary medicine. The challenges of this area of drug delivery arise from the unique anatomy and physiology of the target animal, the cost constraints associated with the value of the animal being treated and the extended periods of time that delivery must be sustained for (often measured in months).

The purpose of this book is to introduce the reader to the unique opportunities and challenges of the field of CRVDDS and to explain and discuss the basic controlled release principles underlying the development of CRVDDS. Its aim is to provide an overview of many of the areas where CRVVDS have application, and to highlight the opportunities and prospects for controlled release technology in the veterinary field.

"Controlled Release Veterinary Drug Delivery" comprises chapters that provide workers in the field (and those interested in this area) with information on the design, development and assessment of a variety of CRVDDS. The book contains chapters that describe the relevant animal physiological and anatomical considerations alongside descriptions of current and emerging controlled release delivery systems for a variety of routes for drug delivery, and present overviews on the physical and chemical assessment of veterinary controlled release delivery systems.

The veterinary area is abound with opportunities for the development of controlled release drug delivery technologies. It is an area of medicine that is open to the acceptance of novel drug delivery devices, and which readily encompasses the use of novel routes of administration. It is an area of many unmet needs, most of which offer opportunities and unique challenges for the innovative formulation scientist to provide solutions. This book will provide an insight into the biological, clinical and pharmaceutical challenges that face the formulation scientist in this interesting and diverse area of research.

This dictionary spans the practice of pharmacology, and of allied sciences insofar as they are related to it, with particular emphasis on the development, regulation and use of human medicine. It is offered to students as well as to professionals in pharmacology and allied sciences for "reference" and for "browsing," and as a bedside book and travelling companion. Its size (approximately 2000 entries) is appropriate for these uses.

Features of this dictionary:

- Provides definitions of terms in pharmacology, both basic and clinical

- Gives information on new medicine development and official regulations

- Covers allied topics, including statistics, ethics, scientific miscounduct, authorship, publication and law.

Now in its tenth edition, this famous compilation of synonyms for drugs, pesticides and other substances of pharmacological or biochemical interest has become even more international and comprehensive in its scope. Electronic storage of the data has ensured that the book is fully up to date, while the highest degree of cross referencing between entries is guaranteed. The types of names presented are: chemical names, abbreviated chemical names, source names, pharmacological names, pesticide names, names derived from places, plants or persons, research code numbers, and proprietary names (trademarks).

For people working in the fields of biochemistry, pharmacology, pharmaceutics, and toxicology, as well as for medical editors and drug regulatory officers, this work will prove to be an indispensable source of information.

This book presents a comprehensive and up to date account of the chemotherapy of parasitic diseases, both human and veterinary. The book starts with an overview of parasitic diseases. The body of the book is divided into two parts: antihelminthic drugs, and antiprotozoal drugs. Both parts start with chapters highlighting the 'biochemical targets' available for chemotherapeutic interference. Individual chapters deal with one chemical class of compounds and describe their origin, structure-activity relationship, mode of action, and methods of synthesis and their status both in clinical and veterinary practice. The book will be useful to a wide spectrum of readers: students embarking on a research career in parasitic chemotherapy, clinicians (and veterinarians) and clinical pharmacologists desiring detailed information about the drugs currently in use, and pharmaceutical technologists wanting to update their knowledge of the methods of manufacture.

"Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation" includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunity within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference.
Multi-contributed book and chapters are written by contributors who are experts in their fieldProvides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may beIncludes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applicationsChapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research

A companion website offers an elaboration on key points and discussion questions and provides patient case scenarios that illustrate how pharmacogenomics may be applied to a clinical setting

"Clinical Pharmacology During Pregnancy" is written for clinicians, physicians, midwives, nurses, pharmacists and other medical professionals directly involved in the care of women during pregnancy. This book focuses on the impact of pregnancy on drug disposition and also includes coverage of treatments for diseases of specific body systems as well as essential content on dosing and efficacy.

The broad range of this book encompasses analgesics, antiasthmatics, antidepressants, heart and circulatory drugs, vitamins and herbal supplements, and more. Topics in chemotherapy and substance abuse are covered, as are research issues, including clinical trial design and ethical considerations.
Uses an evidence-based approach for therapeutics during pregnancyIncludes a summary of specific medications by indication with up-to-date information on dosing and efficacy in pregnancy for the given indicationIncludes a companion website containing support materials for professional or continuing education courses in OB pharmacology

"TherapeuticDrug Monitoring: Newer Drugs andBiomarkers"features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presentsnew and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.

Includes both the technical and clinical issues associated with therapeutic drug monitoring.

Discusses theutility of therapeutic drug monitoring of newer drugs such as antiretroviral agents, anticonvulsants, antidepressants etc.

Provides up-to-date information onissues inpharmacogenomics and personalized medicine with emphasis on therapy with warfarin, certain anticancer drugs and antidepressants.

Covers important content on thelimitations of commercially available immunoassays (chemical tests) for therapeutic drug monitoring and additional analytical techniques. "

Pharmaceuticals companies, biotech companies, and CROs, regardless of size, all face the same challenge of managing costs and operational execution associated with bringing a valuable drugs and devicesto market. Because of timeline pressures and cost as well asthe growing interest in "neglected diseases" and diseases affecting the emerging nations, clinical trials are increasingly conducted in emerging markets and developing countries where infrastructure, leadership, skilled personnel and a governance are at a premium.

Working with academics, regulatory professionals, safety officers, experts from the pharma industry and CROs, the editors have put together thisup-to-date, step-by-step guide book tobuilding and enhancingglobal clinical trial capacity inemerging markets anddeveloping countries. This book covers the design, conduct, and tools to build and/or enhance human capacity to executesuch trials, appealing toindividuals in health ministries, pharmaceutical companies, world health organizations, academia, industry, and non-governmental organizations (NGOs) who are managing global clinical trials.

* Givesmedical professionals the businesstools needed to effectively execute clinical trials throughout the world

* Provides real world international examples which illustrate the practical translation of principles

* Includes forms, templates, and additional references for standardization in a number of global scenarios"

The Side Effects of Drugs Annual was first published in 1977. It has been published continuously since then, as a yearly update to the encyclopaedic volume Meyler's Side Effects of Drugs. Each new Annual provides clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists have contributed to the Annuals by selecting from each year's publications all that is truly new and informative, by critically interpreting it, and by pointing out whatever is misleading. The use of the book is enhanced by separate indexes, allowing the reader to enter the text via the drug name, adverse effect, or drug interaction. Special features of the Annuals are the Side Effects of Drugs Essay, usually written by a guest author, and the special reviews: short articles, within the different chapters, that give extra attention to topics of current interest. The Essay in Annual 27 is entitled 'The General Practice Research Database' (by Dr. H. Jick) and there is a Historical Essay entitled 'Louis Lewin - Meyler's Predecessor' (by Dr. J.K. Aronson). The special reviews in this volume include, among others: The effects of NSAIDs on blood pressure Risks of inhaled corticosteroids in children Leukotriene receptor antagonists and Churg-Strauss syndrome Amiodarone and thyroid disease Surveillance of adverse events following immunization Smallpox vaccination Safety aspects of folic acid Inhibitors of topoisomerase I and topoisomerase II Liver damage from kava kava

Biosensors have captured the imagination of the world's scientific and commercial communities by combining interdisciplinary skills of biologists, physicists, chemists and engineers to provide innovative solutions to analytical problems. Biosensors area pplicable to clinical diagnostics, food analysis, cell culture monitoring, environmental control and various military situations. Ever increasing demands for rapid and convenient analyses of a wide variety of materials in diverse locations has led to intense interest in the fusion of biology and electronics which mimics our principal concern: the effect of materials and environments on living systems. This series "Advances in Biosensors" presents a unique compendium of research papers, in which eminent authorities in the field of biosensors provide an up-to-date overview of their laboratory's contribution, summarizing the primary research as it has appeared, possible scattered, in the journal and conference literature, and reflecting on their findings. The net result will be intense, yet highly readable accounts of the state of the art at this leading edge of analytical technology.

This unique and much needed textbook will meet the rapidly emerging needs of programs training pharmacologic scientists seeking careers in basic research and drug discovery rather than such applied fields as pharmacy and medicine. While the market is crowded with many clinical and therapeutic pharmacology textbooks, the field of pharmacology is booming with the prospects of discovering new drugs, and virtually no extant textbook meets this need at the student level. The market is so bereft of such approaches that many pharmaceutical companies will adopt Hacker, et al. to help train new drug researchers.
The boom in pharmacology is driven by the recent decryption of the human genome and enormous progress in controlling genes and synthesizing proteins, making new and even custom drug design possible. This book makes use of these discoveries in presenting its topics, moving logically from drug receptors to the target molecules drug researchers seek, covering such modern topics along the way as side effects, drug resistance, Pharmacogenomics, and even nutriceuticals, one in a string of culminating chapters on the drug discovery process.
*Uses individual drugs to explain molecular actions
*Full color art program explains molecular and chemical concepts graphically
*Logical structure reflecting the current state of pharmacology and translational research, starting with receptors and finishing with target molecules
*Covers such intricacies as drug resistance and cell death
*Consistent format across chapters and pedagogical strategies make this textbook a superior learning tool

This groundbreaking book covers every aspect of deadly toxic chemicals used as weapons of mass destruction and employed in conflicts, warfare and terrorism. Including findings from experimental as well as clinical studies, this one-of-a-kind handbook is prepared in a very user- friendly format that can easily be followed by students, teachers and researchers, as well as lay people. Stand-alone chapters on individual chemicals and major topics allow the reader to easily access required information without searching through the entire book.
This is the first book that offers in-depth coverage of individual toxicants, target organ toxicity, major incidents, toxic effects in humans, animals and wildlife, biosensors, biomarkers, on-site and laboratory analytical methods, decontamination and detoxification procedures, prophylactic, therapeutic and countermeasures, and the role of homeland security.
Presents a comprehensive look at all aspects of chemical warfare toxicology in one reference work. This saves researchers time in quickly accessing the very latest definitive details on toxicity of specific agents used in chemical warfare as opposed to searching through thousands of journal articles. Will include the most agent-specific information on the market.
Includes detailed coverage of the most exhaustive list of agents possibly used as chemical warfare agents in one source. Section 4: Agents That Can Be Used as Weapons of Mass Destruction ? 25 chapters long. Other books on the market only include a sample selection of specific agents. Offering all possible agents detailed under one cover makes this appealing to a wider audience and saves researchers time.

The Forward will be written by Dr. Tetsuo Satoh, Chiba University, Japan. He is one of the most respected, recognizable authorities on chemical warfare agents which will set the authoritative tone for the book.

Covers risk to humans, animals and the environment equally. Researchers involved in assessing the risks involved with a possible chemical warfare attack and those who are developing response plans to such attacks must look at not only the risks to human health but to our wildlife and environment as well. The holistic approach taken in this book ensures that the researchers have ready access to the details no matter which aspect of the effects of CWA's they might be concerned with.

This volume is aimed in general at scientists who have an interest in deciphering the molecular mechanisms for sequence recognition of DNA. The methods have general applicability to small molecules as well as oligomers and proteins, while the examples provide general principles involved in sequence recognition.

"Neurological Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer s disease, Parkinson s disease, Huntington disease, ALS, and the epilepsies. "Neurological Disorders "has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the second volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" 978-0-12-373861-5, which is also available for purchase individually.
- Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process
- Critical evaluation of animal and translational models improving transition from drug discovery and clinical development
- Emphasis on what results mean to the overall drug discovery process
- Exploration of issues in clinical trial design and conductance in each therapeutic area"

"Psychiatric Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. "Psychiatric Disorders "has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the first volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" 978-0-12-373861-5, andis also available for purchase individually.
Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery processCritical evaluation of animal and translational models improving transition from drug discovery and clinical developmentEmphasizes what results mean to the overall drug discovery processExplores issues in clinical trial design and conductance in each therapeutic areaPsychiatric Disorders is available for purchase individually."

"Reward Deficit Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. "Reward Deficit Disorders "has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. "Reward Deficit Disorders" also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the third volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" 978-0-12-373861-5, which is also available for purchase individually.
Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery processCritical evaluation of animal and translational models improving transition from drug discovery and clinical developmentEmphasizes what results mean to the overall drug discovery processExplores issues in clinical trial design and conductance in each therapeutic areaNeurological Disorders is available for purchase individually.

The rate of neurodevelopmental disabilities, including autism, mental retardation, hearing loss and attention deficit hyperactivity disorder is rising in the United States. Although estimates of the prevalence of these disorders vary, figures from the CDC indicate that 4% of all school age children are developmentally disabled. During infancy, many important milestones in behavioral development are shared between human and nonhuman primates. Learning more about the causes of abnormal development in monkeys has provided important insights into the mechanisms underlying neurodevelopmental disabilities in human infants. This book documents the latest research not commonly found in other references, and provides a comprehensive look at the results from decades of work with nonhuman primates as it relates to child development and disability.
* Includes hot topics such as early chemical exposures, immunological influences on development, low birth weight, endocrine disrupters, pediatric AIDS, origin of childhood psychopathologies and assisted reproductive technology
* Represents the significant body of work accumulated since funding for research on developmental disabilities has increased substantially in recent years

This series describes selected advances in the area of atomic spectroscopy. It is promarily intended for the reader who has a background in atmoic spectroscopy; suitable to the novice and expert. Although a widely used and accepted method for metal and non-metal analysis in a variety of complex samples, "Advances in Atomic Spectroscopy" covers a wide range of materials. Each Chapter will completely cover an area of atomic spectroscopy where rapid development has occurred.

This timely book provides an overview of natural products/botanicals used for the management of insect-pest and diseases. It will help readers to update and widen their knowledge about natural products and their bio-activities against plant pathogens. The volume explores activity, chemistry, toxicity and geographic distribution of plants. Discussions concerning the methodology used for the detection of active principles, their mode of action and commercial prospects are of utmost importance and worthy of note.
* Focuses on recent achievements in natural bio-actives
* Global coverage of natural products / plants
* Targets the most important issues of natural botanicals/ biocides
* Includes innovative ideas with lucid explanations
* Contains specialized chapters, such as, natural control of multi-drug resistant organisms, anti-salmonella agents, natural house-dust-mite control agents, and naturally occurring anti-insect proteins, etc.
* Covers research on bioactives: From Lab to Field and Field to Market
* Includes eco-friendly and economically viable herbal technology

The only comprehensive work to cover all aspects of diuretic agents, the book discusses the pharmacology and toxicology of diuretic agents as well as the physiological effects. Experts in the field present the principles and experimental approaches for the study of interactions between pharmacologic compounds in relation to specific target organs. Diuretic Agents contains information on the mechanisms of action and application of diuretics, and details FDA regulations and pharmaceutical industry guidelines.
Key Features
* Written by experts in the field
* Covers all aspects of diuretic agents
* Includes information on the mechanisms of action and application of diuretics